Research programme: neurodegenerative disorders - Synaptica
Latest Information Update: 24 Jun 2003
Price :
$50 *
At a glance
- Originator Synaptica
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease; Motor neuron disease; Parkinson's disease
Most Recent Events
- 14 May 2001 Preclinical development for Alzheimer's disease in United Kingdom (Unknown route)
- 14 May 2001 Preclinical development for Motor neuron disorders in United Kingdom (Unknown route)
- 14 May 2001 Preclinical development for Parkinson's disease in United Kingdom (Unknown route)